Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intravesical Recombinant Mycobacterium (rMBCG), Intravesical Recombinant Mycobacterium
rBCG · 1 trial · 1 indication
Safety assessments will include demographics/medical history, vital signs, hematology, chemistry, urinalysis, and pregnancy.
| Arm | Type | Description |
|---|---|---|
| Intravesical Recombinant Mycobacterium (rMBCG) | EXPERIMENTAL | Participants will receive an induction course of 1-19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration). |
| Name | Type | Description |
|---|---|---|
| Intravesical Recombinant Mycobacterium (rMBCG) | BIOLOGICAL | 19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration) |
Inclusion Criteria: Participants must meet ALL of the following criteria for inclusion in the study: 1. Male or female participants 18 years of age or older. 2. Histologic confirmation of BCG naïve non-muscle invasive urothelial carcinoma of the bladder (mixed histology tumors allowed if urothelia...
rBCG is an investigational intravesical recombinant Mycobacterium therapy being developed by ImmunityBio, Inc. for non-muscle invasive bladder cancer (NMIBC). It is designed to be given directly into the bladder and is currently in Phase 1 clinical development. It is also known as Intravesical Recombinant Mycobacterium (rMBCG).
rBCG is being studied for non-muscle invasive bladder cancer (NMIBC) in patients who are eligible to receive intravesical Tice BCG. It is an intravesical recombinant Mycobacterium therapy given directly into the bladder. The program is in Phase 1 development and is not approved for any indication.
rBCG is being developed by ImmunityBio, Inc., which trades under the ticker IBRX. The company is running the Phase 1 ResQ133A-NMIBC study of intravesical recombinant Mycobacterium (rMBCG) in participants with NMIBC who are eligible to receive intravesical Tice BCG.
rBCG is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The only registered trial is a Phase 1 study in NMIBC, and it is currently recruiting participants.
rBCG is being evaluated in the Phase 1 ResQ133A-NMIBC trial, registered as NCT06800963. The study is recruiting up to 40 participants with NMIBC who are eligible to receive intravesical Tice BCG. It is an uncontrolled, non-randomized, open-label study enrolling adults aged 18 years and older in the United States.
Yes. rBCG is also known as Intravesical Recombinant Mycobacterium (rMBCG) and Intravesical Recombinant Mycobacterium. These names refer to the same investigational agent developed by ImmunityBio, Inc. for non-muscle invasive bladder cancer, so searches under any of these names point to the same Phase 1 program.